PPLPHARMA.NS Balance Sheet
Piramal Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:43
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹3,363.04 Cr. | ₹3,872.64 Cr. | ₹4,175.98 Cr. | ₹4,450.71 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹852.93 Cr. | ₹565.70 Cr. | ₹489.12 Cr. | ₹799.17 Cr. | CapitalWorkInProgress |
| Goodwill | ₹1,107.51 Cr. | ₹1,122.55 Cr. | ₹1,148.21 Cr. | ₹1,257.43 Cr. | Goodwill |
| Other Intangible Assets | ₹2,772.57 Cr. | ₹2,617.11 Cr. | ₹2,450.85 Cr. | ₹2,583.85 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹41.76 Cr. | ₹34.94 Cr. | ₹44.30 Cr. | ₹60.77 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹217.18 Cr. | ₹471.65 Cr. | ₹443.74 Cr. | ₹521.53 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹9,687.08 Cr. | ₹9,847.34 Cr. | ₹9,880.60 Cr. | ₹10,773.38 Cr. | NoncurrentAssets |
| Inventories | ₹1,681.37 Cr. | ₹2,175.88 Cr. | ₹2,312.70 Cr. | ₹3,064.44 Cr. | Inventories |
| Trade Receivables | ₹1,799.34 Cr. | ₹2,134.43 Cr. | ₹2,349.52 Cr. | ₹2,157.67 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹195.59 Cr. | ₹356.82 Cr. | ₹368.98 Cr. | ₹1,199.88 Cr. | CashAndCashEquivalents |
| Current Investments | ₹427.11 Cr. | ₹144.69 Cr. | ₹19.56 Cr. | ₹131.78 Cr. | CurrentInvestments |
| Other Current Assets | ₹527.68 Cr. | ₹511.02 Cr. | ₹551.80 Cr. | ₹548.67 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹4,835.48 Cr. | ₹5,464.47 Cr. | ₹5,796.99 Cr. | ₹7,191.66 Cr. | CurrentAssets |
| Total Assets | ₹14,522.56 Cr. | ₹15,311.81 Cr. | ₹15,677.59 Cr. | ₹17,965.04 Cr. | Assets |
| Equity Share Capital | ₹1,193.32 Cr. | ₹1,322.95 Cr. | ₹1,324.35 Cr. | ₹1,327.16 Cr. | EquityShareCapital |
| Other Equity | ₹5,580.18 Cr. | ₹6,588.42 Cr. | ₹6,801.12 Cr. | ₹6,835.46 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹6,773.50 Cr. | ₹7,911.37 Cr. | ₹8,125.47 Cr. | ₹8,162.62 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | N/A | N/A | ₹0.00 Cr. | ₹0.00 Cr. | NonControllingInterest |
| Total Equity | ₹6,773.50 Cr. | ₹7,911.37 Cr. | ₹8,125.47 Cr. | ₹8,162.62 Cr. | Equity |
| Long-term Borrowings | ₹3,383.54 Cr. | ₹2,483.75 Cr. | ₹3,214.07 Cr. | ₹4,299.97 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹3,906.01 Cr. | ₹3,031.14 Cr. | ₹3,785.85 Cr. | ₹5,044.14 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹2,121.23 Cr. | ₹2,075.11 Cr. | ₹1,506.20 Cr. | ₹1,195.51 Cr. | BorrowingsCurrent |
| Trade Payables | ₹1,192.71 Cr. | ₹1,538.37 Cr. | ₹1,533.77 Cr. | ₹2,479.11 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹228.92 Cr. | ₹387.37 Cr. | ₹273.87 Cr. | ₹593.21 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹3,843.05 Cr. | ₹4,369.30 Cr. | ₹3,766.27 Cr. | ₹4,758.28 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹14,522.56 Cr. | ₹15,311.81 Cr. | ₹15,677.59 Cr. | ₹17,965.04 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from PPLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).